References
- Braae R, McNee W, Moore D. Managing pharmaceutical expenditure while increasing access. The Pharmaceutical Management Agency (PHARMAC) experience. Pharmacoeconomics16(6), 649–660 (1999).
- Claxton K, Briggs A, Buxton MJ et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ336(7638), 251–254 (2008).
- Birch S, Gafni A. The ‘NICE’ approach to technology assessment: an economics perspective. Health Care Manag. Sci.7(1), 35–41 (2004).
- Detsky AS, Laupacis A. Relevance of cost–effectiveness analysis to clinicians and policy makers. JAMA298(2), 221–224 (2007).
- Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics24(11), 1121–1131 (2006).
- Buxton MJ. Economic evaluation and decision making in the UK. Pharmacoeconomics24(11), 1133–1142 (2006).
- Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics26(2), 91–98 (2008).
- Appleby J, Devlin N, Parkin D. NICE’s cost–effectiveness threshold. BMJ335(7616), 358–359 (2007).
- McCabe C, Claxton K, Culyer AJ. The NICE cost–effectiveness threshold: what it is and what that means. Pharmacoeconomics26(9), 733–744 (2008).
- Cohen J, Stolk E, Niezen M. The increasingly complex fourth hurdle for pharmaceuticals. Pharmacoeconomics25(9), 727–734 (2007).
- Brougham M, Metcalfe S, McNee W. Our advice? Get a budget! Healthc. Pap.3(1), 83–85; discussion 87–94 (2002).
- Grocott R, Metcalfe S. Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. NZ Med. J.118(1223), U1690 (2005).
- Grocott R, Schoeler R, Priest V et al.Prescription for Pharmacoeconomic Analysis – Methods for Cost–Utility Analysis. Version 2. Pharmaceutical Management Agency, PHARMAC, Wellington, New Zealand(2007).